| 2008-06-26: |
Bowel Cancer Patients Live Longer Taking Xeloda
Barcelona, Spain ( PRN/ots ) - - Analysis Confirms That Oral Xeloda is Superior to IV 5 - FU - Not for US Media A pre - planned multivariate analysis of the five - year follow - up data shows that patients receiving chemotherapy after - surgery to treat colon (...) |
| 2008-06-26: |
European Approval for Roche's Pegasys Personalises Treatment for a Subgroup of Hepatitis C Patients: Chance for Cure With Only Four Months of Treatment
Basel, Switzerland ( PRN/ots ) - - Roche Also Announces Start of NCORE Study to Determine Best Length of Treatment in Patients who do not Experience a Rapid Response Roche announced today that the European Commission has approved a shortened, 16 - week course of treatment (...) |
| 2008-06-25: |
Confirmed: Oral Xeloda Should Consistently Replace IV 5 - FU in Treatment of all GI Cancers
Barcelona ( PRN/ots ) - - Not for US Media - Comparative Analysis Shows Chemotherapy Pill Xeloda Should Become Standard of Care in Colon, Colorectal and Stomach Cancers Results from a meta - analysis involving data from six phase III studies show that patients taking the (...) |
| 2008-06-25: |
Leading Colorectal Patient Organisation Calls on EU Countries to Improve Poor Standards of Care
Barcelona, Spain ( PRN/ots ) - europacolon has called on all governments to implement existing EU recommendations on colorectal cancer screening following a new report published today that shows the disease to be significantly neglected despite being the second most common cancer in Europe.( 1 ) Welcoming the (...) |
| 2008-06-25: |
First Comprehensive Report on Colorectal Cancer ( CRC ) Care in Europe and Australia Reveals Urgent Need for Action
London ( PRN/ots ) - - Few Countries Have Prioritised This Potentially Preventable and Curable Cancer The first cross - country report on the management and funding of colorectal cancer ( CRC ) reveals an urgent need for action to improve the survival of patients diagnosed with this (...) |
| 2008-06-25: |
WHO Creates New Surgical Tool to Make Operations Safer Everywhere
Geneva and Washington Dc ( PRN/ots ) - With major surgery now occurring at a rate of 234 million procedures per year - one for every 25 people - and studies indicating that a significant percentage result in preventable complications and deaths, the World Health Organization ( WHO ) (...) |
| 2008-06-18: |
Key Primary Resverlogix Objective Obtained
San Diego, California and Calgary, Canada ( PRN/ots ) - - Findings Demonstrate Clear Trends of Proof of Principle of Reverse Cholesterol Transport in Human Volunteers SAN DIEGO, California and CALGARY, Canada, June 18 /PRNewswire/ - - Resverlogix Corp. ( "Resverlogix" or the "Company" ) ( TSX: RVX ) announced (...) |
| 2008-06-18: |
MICARDIS( R ) - Based Regimens Help More Patients Achieve Their Blood Pressure Goals
Berlin ( PRN/ots ) - - For non - US Healthcare Media and non - UK Healthcare Media - New Studies Show Benefits of MICARDIS( R ) ( Telmisartan ) in Combination With Amlodipine and Hydrochlorothiazide The results of two new studies of MICARDIS( R ) ( telmisartan ) in free combination with amlodipine or (...) |
| 2008-06-17: |
New Study Demonstrates That Lack of Pandemic Planning Will Affect Bottom Line
Toronto, Ontario ( PRN/ots ) - - Latest Evidence for Businesses to Justify Investing in Pandemic Preparedness Plans TORONTO, Ontario, June 17 /PRNewswire/ - - The Schulich School of Business today released the first study to assess the impact of an influenza pandemic on individual companies. Presented (...) |
| 2008-06-16: |
Preterax( R ) Prevents and Reverses Renal Disease in Type 2 Diabetics
Berlin ( PRN/ots ) - New results of the ADVANCE ( Action in Diabetes and Vascular disease: PreterAx and DiamicroN - MR Controlled Evaluation ) trial have been presented today at the European Society of Hypertension ( ESH ) and show that the antihypertensive Preterax - a fixed combination of the ACE - (...) |
| 2008-06-16: |
Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
Lyon, France and Swiftwater, Pennsylvania ( PRN/ots ) - Sanofi Pasteur, the vaccines division of sanofi - aventis Group, announced today its commitment to donate 60 million doses of H5N1 vaccine to the World Health Organization ( WHO ) over 3 years for the establishment of an H5N1 (...) |
| 2008-06-13: |
New Global Survey Exposes Considerable Burden of Fibromyalgia Including Potential Economic Impact
Paris ( PRN/ots ) - - Lack of Physician Education May Contribute to Problem A new global survey of fibromyalgia patients and physicians shows that fibromyalgia, a chronic widespread pain condition, results in poor quality of life and poses a financial burden on patients (...) |
| 2008-06-12: |
New Data Demonstrates Joint Damage is Inhibited With Wyeth's Biologic Enbrel( R ) Plus Methotrexate in Patients With Early Active Rheumatoid Arthritis
Maidenhead, England ( PRN/ots ) - - Study Results Provide Further Evidence That Early Treatment of Rheumatoid Arthritis With Enbrel( R ) Plus Methotrexate in Moderate to Severe Patients can Stop the Disease From Progressing, and Helps Patients Return to More Normal and Productive Lives Data presented (...) |
| 2008-06-11: |
New Meta - Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
Basel, Switzerland ( PRN/ots ) - - Data Published in the British Journal of Cancer Reports That NeoRecormon use has no Negative Impact on Overall Survival or Tumour Progression A new meta - analysis of all 12 prospective, randomised, controlled studies in 2,301 cancer patients shows (...) |
| 2008-06-10: |
New Data Shows Pramipexole ( Mirapexin( R )/Sifrol( R ) ) Can Significantly Reduce Limb Pain in Patients With Restless Legs Syndrome ( RLS )
Ingelheim, Germany ( PRN/ots ) - - First Ever Study to Demonstrate Efficacy of Pramipexole in Treating RLS - Associated Limb Pain - For Healthcare Media Outside the U.S.A. A new study demonstrating that pramipexole ( Mirapexin( R )/Sifrol( R ) ) can significantly reduce RLS - associated limb pain in patients with (...) |
| 2008-06-07: |
GRAZAX( R ) Demonstrates Significant Reductions on Asthma Symptoms in Children
Barcelona ( PRN/ots ) - - In Addition to Effects on Allergic Rhinitis ( Hayfever ), GRAZAX( R ) Demonstrated Significant Reductions in Asthma Symptoms in Children Aged 5 to 16 Years Old ALK - Abelló today presented successful results from a new clinical trial, GT - 12, designed to measure (...) |
| 2008-06-06: |
Revolutionary Healing Technology for Treating Difficult and Chronic Wounds Approved by Health Canada
Toronto, Canada ( PRN/ots ) - Archimed, the woundcare division of Insense Ltd., today announced it has received approval from Health Canada for the use of its revolutionary Oxyzyme product in the treatment of difficult and chronic wounds. Oxyzyme was first trialed in Toronto by Dr. (...) |
| 2008-06-05: |
SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI( Milano )
Calgary, Canada ( PRN/ots ) - - Company Achieves Important Milestone in Development of Next Generation Cardiovascular Drug SemBioSys Genetics Inc. ( TSX:SBS ), a biotechnology company dedicated to developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has demonstrated that (...) |
| 2008-06-04: |
Lymphoma Experts Herald 10 Years of the "Magic Bullet"
Lugano, Switzerland ( PRN/ots ) - - Award and Lecture Mark Anniversary of Monoclonal Antibodies Today, physicians and patient group representatives from around the world celebrated the presentation of the San Salvatore Foundation award for outstanding achievement in the field of malignant lymphoma and the (...) |
| 2008-06-03: |
Isotechnika to Hold Conference Call to Discuss Positive PROMISE Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. will hold a conference call to discuss final Phase 2b PROMISE kidney transplant data for the Company's lead immunosuppressive drug, voclosporin, on Wednesday, June 4th at 9:00 a.m. ET/7:00 a.m. MT. As previously announced, (...) |
| 2008-06-03: |
New Abbott Aluvia( R ) Tablet for Treatment of HIV Available in South Africa
Johannesburg, South Africa ( PRN/ots ) - - More than 5 Million South Africans Living with HIV Gain Access to First and Only Co - formulated, Non - refrigerated Protease Inhibitor Abbott ( NYSE: ABT ) today announced that the new tablet formulation of its protease inhibitor Aluvia( R ) ( lopinavir/ (...) |
| 2008-06-02: |
Bimatoprost / Timolol Fixed Combination Therapy Demonstrates Significantly Better IOP Control Over 12 Hours Compared to Latanoprost / Timolol Combination
Berlin, Germany ( PRN/ots ) - - First Crossover Study to Compare Fixed Combination Therapies Presented at EGS Greater intra - ocular pressure ( IOP ) lowering benefit can be achieved for glaucoma patients treated with a fixed combination of bimatoprost and timolol ( Ganfort( R ), Allergan ), new data presented today (...) |
| 2008-05-31: |
Catumaxomab, Representing a New Generation of Antibodies, Proved Efficient and Safe in Malignant Ascites / Data presented at 44th annual ASCO congress, Chicago, USA
München, Deutschland und Chicago, USA ( na Originaltextservice ) - Treatment with the trifunctional antibody catumaxomab significantly prolongs puncture - free survival in patients with malignant ascites, according to the results from a Phase II/III trial presented at the 44th American Society of Clinical (...) |
| 2008-05-31: |
/K I L L K I L L K I L L - - Merck Serono/
We are advised by Merck Serono that journalists and other readers should disregard the news release "Erbitux Significantly Prolongs Survival in 1st - Line Treatment of Non - Small Cell Lung Cancer" NYSE:SRA, issued today due to premature release. This release will be reissued at (...) |
| 2008-05-31: |
Erbitux Significantly Prolongs Survival in 1st - Line Treatment of Non - Small Cell Lung Cancer
Chicago and Darmstadt, Germany ( PRN/ots ) - - New Data Provides the Basis for the Future Role of Erbitux ( cetuximab ) as a Standard in Combination With Platinum - Based Chemotherapy in the 1st - Line Treatment of Patients With Non - Small Cell Lung Cancer ( NSCLC ) - Location: (...) |
| 2008-05-31: |
Patients With Pancreatic Cancer can Benefit From Avastin( R ) Plus Tarceva( R )
Basel, Switzerland ( PRN/ots ) - - Results Confirm Previously Demonstrated Survival Advantages of Tarceva in This Difficult - to - Treat Disease - ABSTRACT No: 4507 Adding Avastin ( bevacizumab ) to a combination of Tarceva ( erlotinib ) and chemotherapy significantly improves the time patients with metastatic pancreatic cancer live (...) |
| 2008-05-30: |
New Report Shows That Despite Poor Survival Rates Lung Cancer is not Prioritized in Europe
Stockholm ( PRN/ots ) - - Report Benchmarks the Current State of Lung Cancer Care Across Europe The fragmented organization and management of lung cancer diagnosis and care in many European countries are exacerbating already poor survival rates amongst patients with the disease. That is the (...) |
| 2008-05-30: |
Tarceva( R ) Delivers Benefits Across Broad Range of NSCLC Patients - Confirmed by New Data
Chicago, Illinois ( PRN/ots ) - - Tarceva Extends Length and Quality of Life in Largest Non - Small Cell Lung Cancer ( NSCLC ) Phase IV Study Ever Conducted - For non - US and non - UK Media Only New data presented at ASCO 2008 from TRUST( 1 ), (...) |
| 2008-05-30: |
Pertuzumab With Herceptin( R ) Shows Impressive Results in Women With Advanced HER2 - Positive Breast Cancer
Basel, Switzerland ( PRN/ots ) - New data from a Phase II trial presented at the American Society of Clinical Oncology ( ASCO ) 2008 meeting showed that half of the patients with advanced, HER2 - positive metastatic breast cancer whose disease had progressed during a Herceptin - containing regimen (...) |
| 2008-05-29: |
New Published Data Support Safety and Efficacy of RESOLOR( R ) for Treatment of Chronic Constipation
Turnhout, Belgium ( PRN/ots ) - - New Generation Compound Provides Significant Benefit in Patients who do not Adequately Respond to Laxatives New phase III data for RESOLOR( R ) ( prucalopride ) published today in The New England Journal of Medicine ( NEJM ) shows statistically and clinically significant improvement (...) |
| 2008-05-29: |
Movetis Files RESOLOR( R ) With EMEA for the Indication of Chronic Constipation
Turnhout, Belgium ( PRN/ots ) - Movetis today announced that the European Medicines Agency ( EMeA ) has accepted the Marketing Authorization Application ( MAA ) submission for RESOLOR( R ) ( prucalopride ) as a treatment for chronic constipation in adults in whom laxatives fail to provide adequate relief. RESOLOR is a new (...) |
| 2008-05-29: |
Wyeth Receives FDA Fast Track Designation for its 13 - valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
Collegeville, Pennsylvania ( PRN/ots ) - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation to the Company's investigational 13 - valent pneumococcal conjugate vaccine for infants and toddlers. Wyeth is seeking (...) |
| 2008-05-29: |
Drug - Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical Trials
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. announced today that voclosporin is positioned to enter a Phase 1 clinical trial as the drug utilized in the CINATRA( TM ) Drug Coated Coronary Stent system developed by the Company's partner, Atrium Medical Corporation. Atrium has received approval from (...) |
| 2008-05-29: |
World Gastroenterology Organisation and Danone launch Global Campaign to Improve Digestive Health
London ( PRN/ots ) - - Year - Long Campaign Titled 'Optimum Health and Nutrition' to Focus on the Link Between Nutrition and Digestive Health - Poor Digestive Health Affects Millions Worldwide and Seriously Impacts Quality of Life, yet few Seek Medical Advice - WGO and Danone (...) |
| 2008-05-27: |
Isotechnika Reports Final Results of the PROMISE Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. ( TSX:ISA ) today announced positive results from the Phase 2b PROMISE trial which evaluated the Company's lead drug, voclosporin , in de novo kidney transplant patients. This trial was designed to determine the most appropriate dosing strategy for (...) |
| 2008-05-26: |
AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity
Amsterdam, The Netherlands ( PRN/ots ) - - Production Increase Brings Large Disease Areas Within Reach Amsterdam Molecular Therapeutics ( Euronext: AMT ), a leader in the field of human gene therapy, today announced that it obtained a Cooperative Research and Development Agreement from the National Heart, (...) |
| 2008-05-25: |
Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World
Barcelona, Spain ( PRN/ots ) - - In Europe, Less Screening and Treatment, and an Apparent Higher Prevalence of Hip Fracture Than in North America and Australia In a first - of - its - kind study in osteoporosis, one in four women surveyed from Europe, North (...) |
| 2008-05-22: |
AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy
Amsterdam, The Netherlands ( PRN/ots ) - Amsterdam Molecular Therapeutics ( Euronext: AMT ), a leader in the field of human gene therapy, today announced that it obtained a license from La Sapienza University in Rome, Italy, to their advanced small nuclear RNA ( snRNA ) - based exon - skipping technology (...) |
| 2008-05-20: |
Inovelon( R ) a New Treatment for Lennox - Gastaut Syndrome Reduces Drop Attacks by Over 40%
London ( PRN/ots ) - - First EMEA Licensed Treatment Specifically for LGS Offers New Hope for Patients With Epilepsy Eisai Europe Limited, ( Headquarters: London, Chairman and CEO Yutaka Tsuchiya ) today announced publication of the results of a major study of its new anti - epileptic (...) |
| 2008-05-19: |
"Am I Number 12?"
Basel, Switzerland ( PRN/ots ) - - Roche Supports Patient Groups and International Health Bodies to Call for Increased Resources to Fight Viral Hepatitis - a Major Global Killer A staggering one in 12 people globally are estimated to be infected with chronic hepatitis B or (...) |
| 2008-05-16: |
Eribulin Mesylate Demonstrated Anti - Tumor Activity in Heavily Pretreated Patients With Advanced Breast Cancer
London ( PRN/ots ) - - Phase II Data Presented at ASCO Showed Acceptable Tolerability Profile, with Low Incidence of Grade 3 and 4 Neuropathy Eisai Europe Ltd. The investigational chemotherapeutic agent eribulin mesylate ( E7389 ) demonstrated activity in a heavily pretreated population of women with (...) |
| 2008-05-16: |
Abbott Launches Next - Generation StarClose( R ) SE Vascular Closure System
Abbott Park, Illinois ( PRN/ots ) - - New Device Designed to Provide Fast, Safe and Secure Vessel Closure Following Catheterization Procedures Abbott today announced the launch of the StarClose( R ) SE Vascular Closure System, a next - generation vessel closure device engineered to enable fast, safe (...) |
| 2008-05-15: |
Landmark ATHENA Study Findings With Multaq( R )( dronedarone ) Show 24 Prozent Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial Fibrillation
Paris ( PRN/ots ) - Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) announced today that findings from the landmark ATHENA study showed that Multaq( R ) ( dronedarone ), a potential therapy for the treatment of patients with atrial fibrillation or atrial flutter, decreased the risk of cardiovascular hospitalisations or (...) |
| 2008-05-14: |
XIENCE( TM ) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
Barcelona, Spain ( PRN/ots ) - - Data from SPIRIT II and III Clinical Trials Also Show Improvement in Vessel Renarrowing with XIENCE V Compared to TAXUS in Patients with Small Vessels Data presented today from an independent pooled subset analysis of Abbott's SPIRIT II (...) |
| 2008-05-14: |
New Data Support Routine Childhood Vaccination With PREVENAR in Europe
Maidenhead, England ( PRN/ots ) - - PREVENAR Shown to Reduce Invasive Pneumococcal Disease in Young Children Data presented at the 26th annual meeting of the European Society for Paediatric Infectious Diseases ( ESPID ) in Graz, Austria, provide additional evidence of the public health impact of (...) |
| 2008-05-13: |
XIENCE( TM ) V Drug Eluting Stent from Abbott Outperforms Market - Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Barcelona, Spain ( PRN/ots ) - - Patients Treated with XIENCE V in SPIRIT III Trial Experience Better Long - Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients Treated with TAXUS Long - term data presented for the first time today from the SPIRIT III (...) |
| 2008-05-12: |
MIRCERA Keeps Haemoglobin Levels Stable With Significantly Fewer Dose Changes Than With Other ESAs
Basel, Switzerland ( PRN/ots ) - - Dose Adjustments Considered to be one of the Main Causes of Haemoglobin Instability in Chronic Kidney Disease Patients A new analysis has shown that once - monthly Mircera( R ) maintains stable haemoglobin ( Hb ) levels in patients with chronic kidney disease (...) |
| 2008-05-07: |
Astellas' Mycamine( R ) ( micafungin ) Licensed for Use in Europe to Treat Serious Fungal Infections
Staines, England ( PRN/ots ) - The European Medicines Agency ( EMEA ) has announced the marketing authorisation of Mycamine( R ), Astellas Pharma Europe's treatment for invasive candidiasis, oesophageal candidiasis and prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation. Mycamine( R ) will initially be available in the (...) |
| 2008-05-07: |
Women Suffering From Decreased Sexual Desire: Silence Hinders Diagnosis of the Prevalent Condition Hypoactive Sexual Desire Disorder ( HSDD )
Ingelheim, Germany ( PRN/ots ) - - For Non - US Media - Boehringer Ingelheim Announces Commitment to Progressing Science in This Area of Unmet Medical Need With the 'Bouquet' Studies. Data announced at this week's American College of Obstetricians and Gynecologists ( ACOG ) annual clinical meeting suggest (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
